Skip to main content
. Author manuscript; available in PMC: 2012 Nov 18.
Published in final edited form as: Sci Transl Med. 2011 Jul 6;3(90):90ra59. doi: 10.1126/scitranslmed.3002356

Fig. 4.

Fig. 4

Indolent progression of T790M-harboring patient tumors. (A) A subset of patients with EGFR-mutant tumors (n = 114) treated with first-line gefitinib (7) displayed prolonged responses to treatment. The average time on gefitinib before progression was 0.9 years. (B) Serial computed tomography scans from a patient with an EGFR-mutant tumor (ex 19 del) [images from (11)]. (C) Serial bidimensional measurements taken from the time of best response for the patient in panel B illustrate the slow rate of progression in this lesion. (D) Patients receiving first-line erlotinib as part of a phase II trial. Four of 14 patients (28%; patients B, C, D, and H) were continued on treatment with single-agent TKI (erlotinib or gefitinib) for >6 months after RECIST progression. Asterisk denotes the presence of T790M.